MedTrace Logo

High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma

NCT03007823 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-09-12

No results posted yet for this study

Summary

The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of melanoma.

Conditions

Interventions

BIOLOGICAL

High-activity natural killer

Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.

Sponsors & Collaborators

  • Shenzhen Hank Bioengineering Institute

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-01
Primary Completion
2017-12-01
Completion
2019-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03007823 on ClinicalTrials.gov